CX 801
Alternative Names: CX-801Latest Information Update: 13 May 2024
At a glance
- Originator CytomX Therapeutics
- Class Antineoplastics; Immunotherapies; Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon alpha-2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 May 2024 CytomX Therapeutics and Merck enter a clinical trial collaboration and supply agreement for CX 801 in combination with Pembrolizumab for Solid tumours
- 11 Mar 2024 CytomX Therapeutics plans a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in 1H of 2024
- 24 Jan 2024 US FDA approves IND application for CX 801 in Solid tumours